Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Norgine licenses Santarus's immediate-release omeprazole in Europe

This article was originally published in Scrip

Executive Summary

The speciality pharma company Norgine has licensed exclusive development, manufacturing and commercialisation rights to Santarus's immediate-release omeprazole product, Zegerid, in certain Western, central and Eastern European markets. Norgine will pay Santarus $2.5 million up front and up to $10 million in milestones related to regulatory achievements. It will also pay tiered royalties in the mid- to high-teens. Norgine's payments may be reduced for certain reasons, including costs it incurs in obtaining regulatory approval or reimbursement in major markets.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC004975

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel